AstraZeneca (AZN) stock took a nosedive Monday amid reports it’s mulling a mega-merger with Bristol Myers Squibb (BMY).
The combined company would be worth roughly $400 billion, “making it one of the biggest pharmaceutical mergers in history,” RBC Capital Markets analyst Trung Huynh said in a report
The Financial Times first reported the early merger talks. AstraZeneca declined to comment… Related news Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump 7/09/2026 AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. 7/09/2026 AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a